We are live on ! Find out more
FRTX

Fresh Tracks Therapeutics, Inc. Common Stock

Delisted

FRTX was delisted on the 18th of December, 2023.

70 hedge funds and large institutions have $35.7M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2014 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 13 increasing their positions, 21 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

313% more call options, than puts

Call options by funds: $285K | Put options by funds: $69K

10% less funds holding

Funds holding: 7870 (-8)

14% less capital invested

Capital invested by funds: $41.7M → $35.7M (-$6.05M)

36% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 22

38% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 21

Holders
70
Holders Change
-8
Holders Change %
-10.26%
% of All Funds
2.01%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
14
Increased
13
Reduced
21
Closed
22
Calls
$285K
Puts
$69K
Net Calls
+$216K
Net Calls Change
-$28K
Name Holding Trade Value Shares
Change
Change in
Stake
BCM
26
Bridgeway Capital Management
Texas
$122K +$18.8K +5 +19%
CS
27
Credit Suisse
Switzerland
$118K +$56.4K +15 +94%
Millennium Management
28
Millennium Management
New York
$118K +$117K +31 New
Connor, Clark & Lunn Investment Management (CC&L)
29
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$116K
Bank of New York Mellon
30
Bank of New York Mellon
New York
$109K -$293K -78 -74%
SIM
31
Spark Investment Management
New York
$105K +$105K +28 New
HK
32
Horizon Kinetics
New York
$103K
CCMH
33
Cornerstone Capital Management Holdings
New York
$82K +$79K +21 New
EAM
34
Evanson Asset Management
California
$77K
Citigroup
35
Citigroup
New York
$75K -$18.8K -5 -21%
SFM
36
Soros Fund Management
New York
$71K +$67.7K +18 New
U
37
UBS
Switzerland
$64K +$41.4K +11 +183%
EWM
38
Evercore Wealth Management
New York
$60K
State Street
39
State Street
Massachusetts
$59K -$1.33M -354 -96%
Two Sigma Advisers
40
Two Sigma Advisers
New York
$57K +$56.4K +15 New
CCM
41
Coldstream Capital Management
Washington
$56K
BMM
42
Berkshire Money Management
Massachusetts
$45.9K
Citadel Advisors
43
Citadel Advisors
Florida
$45K +$37.6K +10 +500%
Charles Schwab
44
Charles Schwab
California
$42K -$135K -36 -77%
Susquehanna International Group
45
Susquehanna International Group
Pennsylvania
$41K
Group One Trading
46
Group One Trading
Illinois
$40K +$26.3K +7 +233%
PCM
47
Prelude Capital Management
New York
$38K +$37.6K +10 New
BA
48
BlackRock Advisors
Delaware
$36K -$41.4K -11 -55%
NCCM
49
Nine Chapters Capital Management
New Jersey
$35K +$33.9K +9 New
GC
50
Guggenheim Capital
Illinois
$32K -$22.6K -6 -43%

FRTX Hedge Fund Activity: Q2 2014 in Review

70 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q2 2014, worth a combined $35.7M — down 14% from $41.7M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of FRTX and 14 opened new positions — a net loss of 8 holders — while 21 trimmed existing stakes and 13 added.

The largest buyer was Great Point Partners, opening a new position worth an estimated $2.5M. The largest seller was BlackRock Fund Advisors, cutting an estimated $2.26M.

  • 70 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q2 2014, down from 78 in Q1 2014.
  • Funds reported $35.7M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q2 2014, down 14% quarter-over-quarter.
  • 14 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q2 2014 and 22 closed out, a net change of -8 holders.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q2 2014 was Great Point Partners, an estimated $2.5M added.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q2 2014 was BlackRock Fund Advisors, an estimated $2.26M sold.

Based on aggregated 13F filings for Q2 2014.